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Abstract
Background: Though many countries, including China, are moving towards malaria elimination, malaria remains a
major global health threat. Due to the spread of antimalarial drug resistance and the need for innovative medical
products during the elimination phase, further research and development (R&D) of innovative tools in both epidemic
and elimination areas is needed. This study aims to identify the trends and gaps in malaria R&D in China, and aims to
offer suggestions on how China can be more effectively involved in global malaria R&D.
Methods: Quantitative analysis was carried out by collecting data on Chinese malaria-related research programmes
between 1985 and 2014, invention patents in China from 1985 to 2014, and articles published by Chinese researchers
in PubMed and Chinese databases from 2005 to 2014. All data were screened and extracted for numerical analysis and
were categorized into basic sciences, drug/drug resistance, immunology/vaccines, or diagnostics/detection for
chronological and subgroup comparisons.
Results: The number of malaria R&D activities have shown a trend of increase during the past 30 years,
however these activities have fluctuated within the past few years. During the past 10 years, R&D on drug/
drug resistance accounted for the highest percentages of research programmes (32.4%), articles (55.0% in
PubMed and 50.6% in Chinese databases) and patents (45.5%). However, these R&D activities were mainly
related to artemisinin. R&D on immunology/vaccines has been a continuous interest for China’s public entities,
but the focus remains on basic science. R&D in the area of high-efficiency diagnostics has been rarely seen
or reported in China.
Conclusions: China has long been devoted to malaria R&D in multiple areas, including drugs, drug resistance,
immunology and vaccines. R&D on diagnostics has received significantly less attention, however, it should
also be an area where China can make a contribution. More focus on malaria R&D is needed, especially in
the area of diagnostics, if China would like to contribute in a more significant way to global malaria control
and elimination.
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Background
Despite the development of multiple control efforts,
malaria remains a global epidemic with a high burden of
disease, particularly in impoverished regions [1]. Malaria
has been contracted in over 96 countries inhabited by
roughly 3.3 billion people, and approximately 214 mil-
lion cases were recorded in 2014 [2]. Though many
countries, including China, are moving towards malaria
elimination, further research is still necessary, particu-
larly in the areas of diagnostics, monitoring, evaluation
and surveillance [3, 4]. Additionally, emerging chal-
lenges, such as artemisinin resistance and workforce mi-
gration could precipitate new epidemics [5].
A consensus has been reached on the importance of
developing innovative tools to combat malaria and the
new challenges it presents in both epidemic and elimin-
ation areas [6, 7]. For example, targeted treatments are
needed for asymptomatic infections of low parasite
densities in low transmission countries. Field-ready diag-
nostic tools for mass screening and surveillance are
needed to monitor transmission reduction [7]. Novel
drugs are also needed to prepare for the possibility of
widespread artemisinin resistance, especially in vulner-
able populations such as children and pregnant women.
The world expects developing countries to invest in
R&D related to their own health concerns, such as tu-
berculosis and malaria [8]. The report of the Consulta-
tive Expert Working Group on R&D (CEWG) released
by the World Health Organization (WHO) in 2012
proposed that all member states should cooperate and
contribute additional funding to promote R&D into the
diseases that disproportionately affect developing coun-
tries [9]. As one of the largest developing countries,
China has the financial and technical capability to sup-
port medical R&D, and has shown potential in this field
[10]. China has already made considerable progress in
basic and operational research related to antimalarial
technology. For example, China discovered artemisinin
and its use in the treatment of malaria [11].
Continuous R&D is essential for China to combat
malaria-related challenges, especially the multiple occur-
rences of drug resistance in the Greater Mekong Sub-
region [12]. Within this region, malaria transmission is
particularly intense along the borders between Cambodia,
Laos, Myanmar, Thailand and Vietnam [13]. Chloroquine-
resistant falciparum malaria in China was first discovered
in Yunnan in 1973, which led to the withdrawal of Chloro-
quine treatment for falciparum malaria in the 1980s [14].
Moreover, resistance to amodiaquine and sulfadoxine-
pyrimethamine, as well as declining sensitivities to pyro-
naridine and mefloquine were also documented in the
same regions [15, 16]. Although artemisinin combination
therapies (ACTs) are recommended to delay resistance,
drug efficacy studies have detected artemisinin resistance
in the Greater Mekong Subregion, that is similar to the
trend of Chloroquine resistance in the 1980s [2]. P. fal-
ciparum resistance to artemisinin is mostly restricted to
the Greater Mekong Subregion, however, low efficiency
of artemether-lumefantrine treatments among malaria
patients has also been reported in South America [17].
Besides these, data from in vivo testing along the
China-Myanmar border has indicated a markedly lower
dihydroartemisinin-piperaquine sensitivity in Plasmo-
dium falciparum from 2007 to 2013 [18]. The emer-
gence of artemisinin resistance increases the risk of
resistance to the partner medicines in the combination,
which could be a global threat for malaria control and
treatment as no back-up drug for ACTs is currently
available [19].
Therefore, accelerated R&D into alternative malaria-
related products is urgently needed [20]. However, due
to the lack of market incentives and sustainable govern-
mental funding, R&D progress on malarial products has
been slow and the future of malaria R&D is now a con-
cern [3]. Identifying the current situation and the obsta-
cles of malaria R&D in China is essential for future R&D
and is necessary to ensure that limited resources can be
used to address the needs in vitally important areas.
However, until recently, most published articles concern-
ing malaria R&D in China have only analysed literature
or articles, and have primarily focused on disease con-
trol, while less research has studied the overall malaria
R&D situation in China [4, 21].
In this study, data on malaria R&D activities, including
research programmes, articles, and invention patents,
were collected and analysed to illustrate the situation of
malaria R&D activities on basic science, human drugs,
vaccines, and diagnostics in China. Chronological and
subgroup comparisons were drawn to better demon-
strate trends and China’s potential future contributions.
The authors hope this research will better facilitate do-
mestic elimination and prompt China to be more effect-
ively involved in global malaria R&D and elimination.
Methods
Data sources and extraction
Research articles
A systematic search of articles published between January
1st, 2005 and December 31st, 2014 was conducted using
PubMed, China National Knowledge Infrastructure
(CNKI), and Wanfang databases to identify malaria R&D
studies done by researchers in China. We used the follow-
ing search criteria: ((“Malaria”) and ((“Vaccines, Malarial”
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or “Malaria Vaccines”) or (“Drugs, Antimalarial” or “Anti-
malarials”) or (“Diagnosis” or ““Malaria/diagnosis””)) and
(“development” or “research”) and (“China”) and (“2005/
01/01”[PDAT] : “2014/12/31”[PDAT]). The excluded arti-
cles for this study were categorized as follows: review,
education, software, comment, health promotion and
commercial-related topics. The inclusion criteria were as
follows: 1) original studies; 2) conducted in China; 3)
closely related to the research topic. Two researchers
screened the article titles and abstracts independently, and
all abstracts that met the inclusion criteria were confirmed
by a third researcher. Full articles were obtained for fur-
ther exclusion if needed. All the selected articles were
placed into four categories - basic sciences, drugs/drug re-
sistance, immunology/vaccines, and diagnostics/detection.
Research programmes
National Nature Science Foundation of China (NSFC) is
the main channel used by the Chinese government to
support scientific research [22]. Malaria R&D pro-
grammes applied for and funded between 1985 and 2014
were obtained from the NSFC Internet-based Science
Information system, using keywords “malaria” and “Plas-
modium.” Two researchers excluded research on epi-
demiology/control and vector study separately. After
reaching a consensus, they jointly placed the remaining
research into the same four categories as used to classify
the research articles.
Patents
Invention patents were obtained from China’s State
Intellectual Property Office database, which included
“Vaccines” or “Drugs” or “Diagnosis” and “Malaria” in
the body of the text. Patents were mainly selected from
subsectors A61 (Medical or Veterinary Science; Hygiene)
and C12 (Biochemistry; microbiology; enzymology; mu-
tation or genetic engineering) based on the International
Patent Classification system. All patents were filed be-
tween 1985 and 2014 with rights having been granted by
the end of 2012. The bibliographic information and date
of each patent were obtained. After reading the informa-
tion, two researchers excluded patents unrelated to mal-
aria R&D and categorized the remaining patents into at
least one of the three categories – drugs/drug resistance,
immunology/vaccines, or diagnostics/detection.
Data analysis
Since all data were organized in the Excel format (.xls),
they were processed using Excel 2007 (Microsoft, WA,




In total, 100 (out of 322) English articles and 561 (out of
3 705) Chinese articles, 158 (out of 351) research pro-
grammes, 286 (selected from 347) patent applications
and 82 (selected from 143) granted patents were ana-
lysed after the screening. The number of Chinese re-
search programmes and patent applications related to
malaria R&D showed a tendency of increase during the
past 30 years (Figs. 1 and 2). The number of patent
applications in China that met the study criteria rose
dramatically from 21 during the first decade (from 1985
to 1994) to 289 during the third decade (from 2005 to
2014); while during the same intervals, domestic applica-
tions also rose tremendously from 3 to 58 (Fig. 2,
Table 1). Similarly, 65.2% of research programmes were
conducted during the most recent decade, while only 23

































































































Research on basic sciences
Research on diagnostics/detection
Research on drug/drug resistance
Research on immunology/vaccines
Fig. 1 The number of research programmes granted by the National Nature Science Foundation of China (NSFC) related to R&D of malarial
medical product between 1985 and 2014. No granted research was found in 1985 according to the NSFC database using the criteria
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Though R&D activities rapidly increased after the 1980s,
the activities performed by Chinese researchers fluctu-
ated and showed a downward trend within the last
10 years (Fig. 3). Moreover, an imbalance between differ-
ent categories, especially between drug and diagnostics,
were detected in all the activities (Figs. 1 and 2).
R&D on drugs/drug resistance
R&D on drugs/drug resistance accounted for the highest
proportion of research programmes (32.4%), articles pub-
lished in Chinese (55.0% in PubMed and 50.6% in Chinese
databases) and patent applications (45.5%) during the past
decade. Compared to antimalarial drug R&D activities
during the first decade, the number of activities within the
past decade increased over 5.5 times (from 6 to 33 pro-
grammes) and 26 times (from 3 to 80 applications) in re-
search programmes and patent application, respectively.
Chinese applicants filed more patent applications than ap-
plicants outside China on antimalarial drugs. These were
mainly filed for by private entities (Table 1).
Synthesis and pharmacodynamics of artemisinin and
its derivatives were the main focus in China. The num-
ber of R&D activities related to artemisinin was the lar-
gest, with 48.5% (16/33) programmes and 61.8% (21/34)
patent applications. Among 284 articles from Chinese
databases and 55 written by Chinese researchers from
PubMed, preclinical drug studies accounted for the
highest proportion (57.5%), followed by 17.4% on clinical
studies, 17.1% on drug resistance and susceptibility, 6.5%
on drug safety and adverse effects, and 1.5% on other re-
lated subjects such as Glucose-6-phosphate dehydrogen-
ase (G6PD) deficiency.
R&D on immunology/vaccines
R&D on immunology/vaccines mainly focused on im-
munology and vaccine development (26 from PubMed
and 80 from Chinese databases) rather than global
antigenic polymorphism (3 from PubMed and 8 from
Chinese databases). Patent applicants outside China
showed consistently higher interest in this area com-
pared to Chinese applicants (Table 1). Though only
27.5% of programmes and 17.7% of articles from China
were related to R&D on immunology/vaccines during
the past decade, China’s top public entities have continu-
ously focused on this area. In China, vaccine develop-
ment mainly focused on multi-epitope vaccine Malaria
Random Constructed Antigen-1 (M.RCAg-1), screening
of transmission blocking vaccine (TBV) antigen, and
efficacy testing of PfCP2.9.
R&D on diagnostics/detection
Globally, R&D on diagnostics and detection has mainly
focused on diagnostic tools (78.9%) rather than bio-
markers or detection of low parasitemia. R&D on
serology-based assays and molecular-based approaches,
such as rapid diagnostic tests (RDTs) and loop-mediated
isothermal amplification (LAMP), have opened up new
avenues for major improvements in malaria diagnostics.
However, few R&D activities related to diagnostics were
detected in China. Among them even fewer were related
to novel approaches like LAMP (Figs. 1 and 2). The
number of Chinese domestic patent applications did not
show a significant increase during the past 30 years,
while an increase was observed in foreign private entities










































































































































Applications for drug/drug resistance
Applications for immunology/vaccines
Domestic Applications  in China
Fig. 2 The number of total applications related to R&D of malarial medical product in China and the number of its domestic applications
between 1985 and 2014. No applications were seen in 1985 under our research criteria
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Research on basic science
In total, 110 (16.6%) articles written by Chinese re-
searchers and 29 (31.9%) NSFC-funded programmes
were related to basic science between 2005 and 2014.
Genetics and development of Plasmodium was observed
to be China’s main focus. This accounted for 48.2% of
articles and 75.9% of NSFC programmes in the category
of basic science. China’s emphasis on basic science, espe-
cially on Plasmodium, has proven to be a solid founda-
tion and a great advantage for China in accelerating
R&D on malaria drugs, vaccines, and diagnostics.
Discussion
In this study, quantitative analysis was carried out to
identify trends and potential gaps in China’s malaria
R&D. Results showed that the number of malaria R&D
programmes and patents increased tremendously during
the past three decades. However, these activities have
fluctuated within the past 3 years. This tendency could
potentially be associated with China’s progress in com-
bating malaria, and the notable shift of focus from com-
municable diseases to non-communicable diseases [23].
Our results indicated imbalanced malaria-related R&D
activities among different categories in China, with most
reported activities focused on antimalarial drugs and
fewer related to diagnostics.
It is widely accepted that the R&D on malaria drugs,
vaccines, and diagnostics is not only essential for epi-
demic areas, but also crucial for countries moving to-
wards elimination [24, 25]. Indeed, significant R&D
achievements have been made during the past few de-
cades, such as ACTs, RDTs, and the RTS,S/AS01 malaria
vaccine [4, 26]. The completion of genome sequences
and stage-specific transcriptomes of the intraerythrocytic
developmental cycle of Plasmodium falciparum and P.
vivax may also lead to the discovery of new drugs and
accelerate vaccine development [27–29]. However, most
of these contributions were made by developed countries
and foundations [20]. The world is expecting developing
countries such as China to take on more research re-
sponsibilities, including technical and financial support
[8, 9]. This study shows that China has long been de-
voted to malaria R&D on drugs/drug resistance, basic
science, as well as immunology/vaccines, and may have
the foundation to contribute to world malaria R&D.
China is expected to continue its R&D activities on
malarial drugs, especially after winning the Nobel Prize
for the discovery of artemisinin [30]. This research used
the NSFC programme to illustrate the advantages and
potential interests in malaria R&D, because of NSFC’s
unique unlimited-topic application and selective peer-
review system [22]. The high proportion (and increasing
number) of NSFC-funded programmes and institutes
interested in drugs strongly suggests that malaria re-
searchers in China are primarily interested in antimalar-
ial drugs. Furthermore, R&D on antimalarial treatments
should continue to thrive due to China’s long history of
traditional medicine. Indeed, preclinical studies on
Chinese traditional medicine and new drug candidates
for antimalarial use were seen in the R&D activities.
However, R&D related to artemisinin and ACTs are still
the main focus in China, which could impede China’s
progress in new drug development.
Based on past experience with the spread of resist-
ance to chloroquine and sulfadoxine-pyrimethamine, it
is feared that artemisinin resistance will become wide-
spread within a decade [31]. Though ACTs are ex-
pected to delay resistance, an acceleration of R&D
activities for alternative antimalarial drugs is urgently














Patents applied by Chinese
Programs granted in China
Articles published in Pubmed by Chinese
Fig. 3 The numbers of research programmes granted by National Nature Science Foundation of China, articles published in PubMed by Chinese
authors, and patents applied by Chinese related to R&D of malarial medical product between 2005 and 2014
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10 new antimalarial drugs in various stages, such as the
new antimalarial compound OZ439 [32, 33]. Routine
monitoring and surveillance, as recommended by the
WHO Global Plan for Artemisinin Resistance Contain-
ment, should be strengthened [34]. Unfortunately, this
study shows that artemisinin-based drugs are still the
main focus for researchers in China [35]. Concerns have
been raised about the sustainability of R&D on antimalar-
ial drugs, especially in a post-artemisinin world.
The recent decrease in the number of NSFC pro-
grammes and patent applications related to antimalarial
drugs may also be an area of concern. This decrease
may be the result of falling national support for malaria
R&D after the burden of the disease has decreased in
China [24]. Though prophylactic chemotherapy was sug-
gested in high-transmission settings, the increasing cases
of imported malaria from Southeast Asian and African
countries have resulted in the spread of antimalarial
drug resistances in China [24]. In addition, though most
R&D activities focused on P. falciparum, regions of
China are showing a predominance of P. vivax [36]. P.
vivax is more difficult to control and eliminate than P.
falciparum because of its tendency to relapse after reso-
lution of the primary infection [3]. However, first-line
therapies for the radical cure of vivax malaria - chloro-
quine and primaquine - have not changed in 60 years
[37]. According to a systematic review of the resistance
of P. vivax to chloroquine, chloroquine-resistant P. vivax
is now present across most vivax-endemic regions [38].
All of the above challenges indicate that continued R&D
activities are needed to achieve real malaria elimination.
Vaccines are considered amongst the most important
modalities for potential prevention and reduction of
malaria transmission [6]. However, the complexity of the
P. falciparum life cycle, antigen polymorphism and lack
of understanding for the protective immune mechanism
have made vaccine development a daunting task [39].
Despite RTS,S - the only vaccine currently in Phase 3
clinical trials, there is no licensed malaria vaccine [40].
In this study, patent applicants from other countries
showed consistently higher interest in vaccines since
1985 than Chinese domestic applicants. Domestic com-
parisons also indicated less R&D interest in vaccine than
antimalarial drugs in China. However, the research indi-
cated that China might have more potential in this cat-
egory, since China’s top public entities in malaria
research have been continuously focused on R&D on
immunology/vaccines along with related basic science
studies. Recently, M.RCAg-1 developed by Chinese sci-
entists, was proven efficient in a pilot scale and was
identified for its immunogenicity [41]. Vaccine candidate
PfCP2.9 from China is listed on the WHO malaria vac-
cine rainbow table. And many antigens such as Pvs25
and Pvs28 were screened and tested for the development
of TBV [42]. R&D on immunology/vaccines might be
more promising than antimalarial drugs in China, how-
ever, continuous governmental support is essential for this
time-consuming and costly battle.
Though efforts were seen in multiple R&D areas, the
gaps between China and global malaria R&D are quite
obvious, especially in the field of diagnostics and detec-
tion, as also mentioned by other studies [4, 35]. New
screening tools and better diagnostic tools are recom-
mended to be higher priorities for operational R&D, es-
pecially for countries moving towards elimination [4].
Field-ready active testing for mass screening and sensitive
diagnostic tools for asymptomatic patients are necessary
for global malaria elimination [7]. A number of specific
serology-based assays (FAST-ELISA, RDTs), molecular-
based approaches (LAMP) and proteomic technology for
the discovery of biomarkers have emerged, and have been
proven feasible in field settings with limited technical re-
sources [4]. However, few R&D activities related to diag-
nostics were detected in China by this study. Also, the
existing studies mainly focused on PCR, ELISA or RDTs,
rather than novel approaches like LAMP. Effective bio-
markers are also urgently needed to distinguish imported
cases from local cases during the elimination stage. Unfor-
tunately, in agreement with Zheng’s study, only a few
activities related to this area were detected [35].
The current national strategy of China forcefully pushes
for independent drug innovations to gain a competitive
edge in the global market. From the authors’ point of
view, China should encourage more international R&D
cooperation, especially when it comes to infectious dis-
eases or diseases mainly affecting developing countries. It
is suggested by a US researcher that Sino-US scientific
collaborations could be a powerful and winning combin-
ation to fight against globally neglected tropical diseases,
and this collaboration should also include African scien-
tists [43]. Beyond the potential benefits to China’s reputa-
tion, it is worth reflecting on broader benefits; more
experience in international cooperation and better under-
standing of global R&D policy and practice. All of these
will not only benefit China’s future involvement in global
R&D, but also inject new forces to improve R&D on anti-
malarial products.
Though this was the first research that studied mul-
tiple malaria-related R&D activities in China, it is still
subject to several limitations. Firstly, although vector
control is an essential component for reduction of mal-
aria transmission [44], research related to entomology
and insecticides are not included here since human
medical products are the focus of this study. Secondly,
this study did not deliberately demarcate medical prod-
ucts for P. vivax and P. falciparum during data analysis,
which otherwise might provide additional R&D sugges-
tions. Also, though PubMed, Wanfang and CNKI were
Huang et al. Infectious Diseases of Poverty  (2017) 6:4 Page 7 of 9
consciously selected in the hope of collecting all R&D
related articles, these databases might not include some
articles, not to mention research that remains unpub-
lished or had negative results.
Conclusions
This study indicated that China has long been devoted
to malaria R&D on drug/drug resistance, basic science,
and immunology/vaccines, while R&D related to diag-
nostics and detection of malaria is a major research gap
for China. Continuous focus and international cooper-
ation on malaria R&D is recommended for China to
achieve domestic elimination and contribute to global
malaria control and elimination.
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